[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"},{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"08b3645d-28d9-4926-944c-8d9172259629","acronym":"EA2176","url":"https://clinicaltrials.gov/study/NCT04444921","created_at":"2022-06-08T21:54:15.614Z","updated_at":"2025-02-25T16:37:57.967Z","phase":"Phase 3","brief_title":"EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients","source_id_and_acronym":"NCT04444921 - EA2176","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • carboplatin • paclitaxel • ABP 206 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-06"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"6aa9397c-dbd3-4469-bb16-38aa46f9a03f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03233711","created_at":"2021-01-18T15:58:43.033Z","updated_at":"2025-02-25T16:36:57.514Z","phase":"Phase 3","brief_title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","source_id_and_acronym":"NCT03233711","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD4","pipe":"","alterations":" ","tags":["IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 344","initiation":"Initiation: 07/05/2018","start_date":" 07/05/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"4f82c263-5191-440b-b1f7-d234cfb0ecd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05969860","created_at":"2023-08-01T15:10:04.032Z","updated_at":"2025-02-25T17:39:06.594Z","phase":"Phase 2","brief_title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer","source_id_and_acronym":"NCT05969860","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 06/14/2025","primary_completion_date":" 06/14/2025","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-01-29"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"7f32c6ae-db00-48e3-960e-6cced44274a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05973487","created_at":"2023-08-03T15:09:34.671Z","updated_at":"2024-07-02T16:34:25.733Z","phase":"Phase 1","brief_title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","source_id_and_acronym":"NCT05973487","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A • PRAME • HLA-C","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-06-14"},{"id":"a8ca3ddd-1fe4-4bff-958a-d239de57eafd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02314169","created_at":"2021-01-18T10:57:45.020Z","updated_at":"2024-07-02T16:34:25.697Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer","source_id_and_acronym":"NCT02314169","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 05/13/2015","start_date":" 05/13/2015","primary_txt":" Primary completion: 02/15/2025","primary_completion_date":" 02/15/2025","study_txt":" Completion: 02/15/2025","study_completion_date":" 02/15/2025","last_update_posted":"2024-06-14"},{"id":"351db7f3-6d9a-4613-9f48-4b25eb1e0b71","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894618","created_at":"2021-01-18T19:11:01.852Z","updated_at":"2024-07-02T16:34:26.954Z","phase":"Phase 1","brief_title":"SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT03894618","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK fusion","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-279252"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/26/2019","start_date":" 03/26/2019","primary_txt":" Primary completion: 05/04/2023","primary_completion_date":" 05/04/2023","study_txt":" Completion: 05/04/2023","study_completion_date":" 05/04/2023","last_update_posted":"2024-06-12"},{"id":"8ca01846-5fd8-4a2a-a6c9-f8da5e055a47","acronym":"POD1UM-303","url":"https://clinicaltrials.gov/study/NCT04472429","created_at":"2021-01-29T07:20:57.236Z","updated_at":"2024-07-02T16:34:37.843Z","phase":"Phase 3","brief_title":"Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).","source_id_and_acronym":"NCT04472429 - POD1UM-303","lead_sponsor":"Incyte Corporation","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 308","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 10/27/2024","study_completion_date":" 10/27/2024","last_update_posted":"2024-06-06"},{"id":"753da841-0c33-4a39-9286-8ff2dd2128fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04328740","created_at":"2021-12-16T17:54:55.099Z","updated_at":"2024-07-02T16:35:03.026Z","phase":"Phase 1","brief_title":"Phase 1 Study of Oral TP-1454","source_id_and_acronym":"NCT04328740","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • TP-1454"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-05-17"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"50b1d2ff-2ef3-453b-9f2f-2564d9c8d558","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616196","created_at":"2021-01-19T20:33:33.968Z","updated_at":"2024-07-02T16:35:04.204Z","phase":"Phase 1/2","brief_title":"Study of NKTR 255 in Combination With Cetuximab in Solid Tumors","source_id_and_acronym":"NCT04616196","lead_sponsor":"Nektar Therapeutics","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • avipendekin pegol (NKTR-255)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2024-05-13"},{"id":"4f044f18-3e23-4009-90ad-d13973fbf09d","acronym":"KEYNOTE-158","url":"https://clinicaltrials.gov/study/NCT02628067","created_at":"2021-01-17T17:22:08.805Z","updated_at":"2024-07-02T16:35:04.350Z","phase":"Phase 2","brief_title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","source_id_and_acronym":"NCT02628067 - KEYNOTE-158","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1609","initiation":"Initiation: 12/18/2015","start_date":" 12/18/2015","primary_txt":" Primary completion: 05/04/2027","primary_completion_date":" 05/04/2027","study_txt":" Completion: 05/04/2027","study_completion_date":" 05/04/2027","last_update_posted":"2024-05-10"},{"id":"57397363-0511-4a2f-8250-e63a2ec68211","acronym":"","url":"https://clinicaltrials.gov/study/NCT05018273","created_at":"2021-08-24T11:52:53.229Z","updated_at":"2024-07-02T16:35:07.237Z","phase":"Phase 1","brief_title":"Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors","source_id_and_acronym":"NCT05018273","lead_sponsor":"Nykode Therapeutics ASA","biomarkers":" CRP","pipe":" | ","alterations":" MSI-H/dMMR","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • VB10.NEO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-29"},{"id":"a264e99a-347f-4737-a295-a9c2c9f14c53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05060471","created_at":"2021-09-29T11:53:44.991Z","updated_at":"2024-07-02T16:35:07.827Z","phase":"Phase 2","brief_title":"PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients","source_id_and_acronym":"NCT05060471","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 27","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 04/22/2024","primary_completion_date":" 04/22/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-24"},{"id":"43f9829a-fbb2-49ae-a022-93bd3aff42fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02408861","created_at":"2021-01-18T11:30:20.490Z","updated_at":"2024-07-02T16:35:12.161Z","phase":"Phase 1","brief_title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02408861","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • CD4","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/21/2015","start_date":" 10/21/2015","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-01"},{"id":"8913021c-0691-4041-8da2-58bf2b021f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT06327568","created_at":"2024-03-26T16:39:44.897Z","updated_at":"2024-07-02T16:35:12.807Z","phase":"","brief_title":"Anal Cancer and/or Precancer Screening: Performance Analysis of the BD Onclarity™ HPV Assay on Anal Specimens","source_id_and_acronym":"NCT06327568","lead_sponsor":"European Institute of Oncology","biomarkers":" HBB","pipe":"","alterations":" ","tags":["HBB"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/17/2022","start_date":" 06/17/2022","primary_txt":" Primary completion: 06/17/2026","primary_completion_date":" 06/17/2026","study_txt":" Completion: 06/17/2029","study_completion_date":" 06/17/2029","last_update_posted":"2024-03-26"}]